BMJ Open Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer: the combiCaRe study

Susanne Roth,¹ Christoph Springfield,² Markus K Diener,¹ Christine Tjaden,¹ Phillip Knebel,¹ Ulla Klaiber,¹ Christoph W Michalski,³ Markus Mieth,¹ Dirk Jäger,² Markus W Büchler,¹ Thilo Hackert¹

To cite: Roth S, Springfield C, Diener MK, *et al.* Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer: the combiCaRe study. *BMJ Open* 2019;**9**:e028696. doi:10.1136/bmjopen-2018-028696

► Prepublication history for this paper is available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2018-028696>).

Received 19 December 2018

Revised 29 May 2019

Accepted 08 July 2019

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Thilo Hackert;
Thilo.Hackert@med.uni-heidelberg.de

ABSTRACT

Introduction Pancreatic cancer is a devastating disease with an exceptionally poor prognosis. Complete resection of the primary tumour followed by adjuvant chemotherapy is the current standard treatment for patients with resectable disease and the only curative treatment option. However, long-term survival remains rare. Tumour cell dissemination due to manipulation during surgery may increase the rate of future metastases and local recurrence, and perioperative chemotherapy might diminish local, distant and circulating minimal residual disease. Yet, safety and feasibility of systemic chemotherapeutic treatments during pancreatic cancer resection have to be evaluated in a first instance.

Methods and analysis This is a prospective, single-centre phase I/II feasibility study to investigate the safety and tolerability of a combination of intraoperative chemotherapy and surgical resection in pancreatic cancer. Forty patients with locally confined or borderline resectable pancreatic cancer, meeting all proposed criteria will be included. Participants will receive 400 mg/m² calcium folinate over 2 hours and 2000 mg/m² 5-fluorouracil over 48 hours, started on the day before pancreatic surgery and thus continuing during surgery. Participants will be followed until 60 days after surgery. The primary endpoint is the 30-day overall complication rate according to the Clavien-Dindo classification. Secondary endpoints comprise toxicity and treatment associated complications. Patients receiving perioperative chemotherapy will be compared with a propensity score matched contemporary control group of 70 patients with pancreatic cancer receiving the standard treatment. This trial also contains an ancillary translational study to analyse disseminated tumour cells and effects of pharmacological interventions in pancreatic cancer.

Ethics and dissemination CombiCaRe has been approved by the German Federal Institute for Drugs and Medical Devices (reference number 4042787) and

Strengths and limitations of this study

- This is the first prospective clinical safety and feasibility study to evaluate a novel concept of systemic intraoperative chemotherapy during pancreatic cancer surgery.
- A strength of this study is the careful monitoring of any potential toxicity and treatment related complications and the comparison of the safety profile of this multimodal therapy compared with the standard treatment by inclusion of a propensity score matched contemporary control group.
- If intraoperative chemotherapy during pancreatic cancer surgery proves to be safe, the data will be used as a baseline for a randomised controlled, phase III trial on the oncological effectiveness of this treatment.
- This study will provide valuable information for a better understanding of tumour cell dissemination and effects of pharmacological interventions in pancreatic cancer.

the Medical Ethics Committee of Heidelberg University (reference number AFmo-269/2018). The results of this trial will be presented at national and international conferences and published in peer-reviewed journals.

Trial registration number German Clinical Trials Register (DRKS00015766).

INTRODUCTION

Pancreatic cancer is the fourth leading cause of cancer-related deaths in the Western world, and it is one of only a few cancers for which mortality has increased since 1990.¹ In addition, mortality is projected to further increase,

making this devastating disease the second leading cause of cancer-related death within the upcoming decade. With a 5-year survival rate of about 8%,¹² the prognosis of pancreatic cancer is still very poor.

Surgical resection is the only curative treatment option, and primary surgery followed by adjuvant chemotherapy is the current standard treatment for patients with resectable pancreatic cancer.^{3–6} Local resectability of pancreatic cancer is determined by the involvement of adjacent major vessels and neighbouring organs. An international consensus on the classification of resectability, especially of borderline resectable pancreatic cancer, has recently been developed by the International Study Group of Pancreatic Surgery (ISGPS)⁷ and the International Association of Pancreatology.⁸ However, only a minority of patients are diagnosed with resectable disease and even after potentially curative R0 resection, the 5-year survival rate remains 15%–30%.^{9–13} The cornerstone of tumour resection in pancreatic cancer treatment has been further corroborated by a National Cancer Data Base study in the USA, which showed that the 5-year survival rate of patients with resectable pancreatic cancer drops below 3% if surgery is omitted.¹² Following resection, adjuvant chemotherapy offers a survival benefit for pancreatic cancer patients, and numerous multicentre randomised trials performed over the past two decades showed considerable advances of chemotherapeutic regimens in the adjuvant setting.^{13–25} Additional progress has been made in increasing the resection rate of locally advanced unresectable pancreatic cancer by neoadjuvant chemotherapy, especially combinations of calcium folinate, 5-fluorouracil (5-FU), irinotecan and oxaliplatin (FOLFIRINOX),²⁶ associated with improved overall survival and potential cure. Neoadjuvant chemo-(radio)therapy might also be beneficial in patients with resectable or borderline resectable pancreatic cancer.^{27–29}

Besides improvements in chemotherapeutic regimens, the safety of pancreatic surgery has considerably increased, with a reduction of postoperative mortality to 3%,¹¹ which is mainly due to advances in complication management, especially at high-volume pancreatic surgery centres.^{11 30–32} The most common and serious complication following pancreatic surgery is a leakage of pancreatic juice containing digestive enzymes out of the remnant pancreas, a so-called postoperative pancreatic fistula (POPF).^{33 34} The aggressive nature of the leaking pancreatic juice might cause life-threatening complications, including postpancreatectomy haemorrhage (PPH), or intra-abdominal fluid collection with superinfection leading to abscess formation and sepsis. These complications, together with delayed gastric emptying (DGE) and chyle leak following pancreatic surgery, have been comprehensively defined by the ISGPS with associated severity gradings.^{33–37} Postoperative complications might delay adjuvant treatments or compromise their completeness, associated with diminished effectivity and increased risk of recurrent disease.

Despite advances in surgery and (neo)adjuvant chemotherapy long-term survival of pancreatic cancer patients is

still rare, due to frequent local or systemic recurrence,^{38–40} while the pathophysiology of recurrence remains largely unknown. Subclinical metastasis might occur early during tumour development,^{41 42} but iatrogenic tumour cell dissemination as a result of tumour manipulation during surgery is also a relevant concern.^{43 44} There is evidence that cancer cells are continuously released from the primary tumour into the bloodstream and lymphatic system, and circulating tumour cells (CTCs) are further increased by standard pancreaticoduodenectomy.⁴⁴ Several studies have shown that high levels of CTCs are associated with tumour progression and poor prognosis in patients with pancreatic cancer.^{45–47} Since surgical manipulation of the tumour during pancreatic resection leads to dissemination of pancreatic cancer cells potentially founding the seeds for future metastases and local recurrence, perioperative systemic chemotherapy may reduce recurrence and thereby increase long-term survival by targeting intraoperatively shed cells as well as pre-existing micrometastases. Computational modelling of pancreatic cancer progression indicates that tumour cell growth inhibiting therapies earlier in the course of treatment are even more effective than upfront tumour resection.⁴¹ So far, for pancreatic cancer, no systemic intraoperative chemotherapeutic regimen has been studied in a standardised prospective manner to potentially reduce local and distant recurrences by targeting minimal residual disease such as CTCs. There is limited evidence available demonstrating hyperthermic intraperitoneal chemotherapy (HIPEC) with gemcitabine after R0 pancreatic cancer resection leads to a survival benefit by controlling locoregional recurrence without increasing perioperative morbidity and mortality.⁴⁸ Cytoreductive surgery including multiorgan resection combined with HIPEC is a well-established treatment option for peritoneal carcinomatosis of several gastrointestinal tumour entities, and the operative risk of the procedure has been shown to be similar to any other major gastrointestinal surgery.^{49 50} Likewise, perioperative chemotherapy including pancreatic and hepatic arterial infusion of 5-FU up to 1 week prior to pancreatic cancer resection and restarted again 1 week after surgery seemed to be safe and contribute to survival.⁵¹ Therefore, intraoperative systemic chemotherapy during pancreatic resections should be well tolerated.

Thus, a multimodal treatment concept with a combination of intraoperative Chemotherapy and surgical Resection in patients with locally confined or borderline resectable pancreatic cancer (combiCaRe study) has been developed. Based on the above-mentioned rationale, it has been hypothesised that the number of CTCs can be reduced by this approach. This might translate into a longer interval from pancreatic cancer resection to tumour recurrence and extended overall survival. Because intraoperative chemotherapy for pancreatic cancer has not been tested in a standardised prospective trial, the feasibility and safety of this approach will be evaluated within this prospective, monocentric phase I/II study. In addition, translational

aspects of tumour cell dissemination as well as effects of chemotherapy in pancreatic cancer tissue and blood will be determined. As a proof of concept, the combiCaRe study aims to define the basis for a consecutive confirmatory phase III clinical trial investigating the oncological benefit of this multimodal treatment.

METHODS AND ANALYSIS

Study design

The combiCaRe trial is a prospective, monocentric phase I/II clinical study, conducted at the high-volume pancreatic surgery centre of Heidelberg University Hospital (Germany) to determine the feasibility and safety of a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer. The study protocol adheres to the Standard Protocol Items: Recommendations for Interventional Trials recommendations.⁵²

After screening for eligibility, written informed consent and enrolment to the trial, chemotherapy with 5-FU and calcium folinate will be started the day prior to surgery. Thereby adequate levels of cytotoxic substances will be reached within the systemic circulation during the critical period of tumour manipulation and potential intraoperative tumour cell dissemination. Pancreatic cancer surgery will be performed according to the standards of care in the Department of Surgery at Heidelberg University Hospital. Administration of chemotherapy will be continued for 48 hours in total. Postoperative care will be provided according to regular standards with particular attention to chemotherapy associated side effects. Adjuvant treatment regimens are performed according to current guidelines, starting up to 12 weeks after surgery. The study flowchart is presented in figure 1.

Study population and eligibility criteria

Patients with newly diagnosed resectable or borderline resectable pancreatic cancer as defined by the ISGPS,⁷ located in the head of the pancreas, scheduled for elective primary pancreatic cancer resection will be approached for participation in this study. All patients will be informed in detail about the purpose of the trial, the surgical procedure, the perioperative chemotherapeutic treatment and potential benefits as well as risks. If the patient has given written informed consent to participate in the trial, inclusion and exclusion criteria (box 1) will be carefully evaluated. Eligible patients will be enrolled into the trial. Screened patients who are not enrolled will be documented in the screening log, including the reasons for exclusion.

Subject withdrawal

Subjects may withdraw their consent at any time, without stating the reason and without any disadvantage. Patients may also be excluded for other reasons, if the investigator assesses a continuation of the treatment as detrimental to the subject's well-being.

Sample size

This exploratory study focuses on the feasibility and safety of the therapeutic interventions. No formal sample size calculation has been performed. Therefore, we have chosen a number of patients, which is estimated to be sufficient to obtain first data on feasibility and safety of the intervention. Forty patients are planned to be enrolled in this trial, including five patients who potentially drop out intraoperatively, for example, due to liver or peritoneal metastasis revealed by exploratory laparotomy. To compare the outcomes of the intervention group with a similar control group, the enrolled patients will be matched by propensity score with a contemporary cohort (age, procedures, histopathological findings and medical history) extracted from the pancreatic surgery databases of the Department of Surgery at Heidelberg University Hospital in a 1:2 ratio. This sample size (35:70) would be large enough to detect a standardised mean difference (Cohen's *d*) of about 0.6 with 80% power and a significance level of 5%. A subsequent randomised controlled trial is planned with further sample size calculation based on the results of this trial and all other available data.

Figure 1 Study flowchart. POD, postoperative day.

Box 1 Major inclusion and exclusion criteria of the trial**Inclusion criteria**

- ▶ Newly diagnosed, resectable or borderline resectable pancreatic cancer located in the head of the pancreas, without arterial involvement on cross-sectional imaging (contrast-enhanced CT scan) according to the International Study Group of Pancreatic Surgery criteria.⁷
- ▶ Histologically or cytologically proven pancreatic ductal adenocarcinoma (including variants).
- ▶ ≥ 18 and ≤ 75 years of age.
- ▶ Capacity to consent.
- ▶ Written informed consent.
- ▶ Eastern Cooperative Oncology Group performance status 0–2.
- ▶ Patient considered to tolerate surgery and chemotherapy by a multidisciplinary team.
- ▶ Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. Childbearing potential is defined according to the 'recommendations related to contraception and pregnancy testing in clinical trials' of the Clinical Trial Facilitation Group.

Exclusion criteria

- ▶ Distant metastatic disease.
- ▶ Renal disease, creatinine clearance <50 mL/min (estimated by Cockcroft-Gault).
- ▶ Abnormal hepatic function as defined by a total bilirubin level >1.5 × the upper limit of normal (ULN), unless the patient has extrahepatic cholestasis due to pancreatic cancer, or alanine aminotransferase >2.5 × ULN, liver cirrhosis (of any Child-Pugh grade).
- ▶ Serious cardiovascular disease (eg, myocardial infarction in the last 12 months, congestive heart failure New York Heart Association (NYHA) III/IV, unstable angina pectoris).
- ▶ Severe chronic obstructive pulmonary disease, Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage >II.
- ▶ American Society of Anesthesiologists (ASA) score >III.
- ▶ Active infection, including cholangitis.
- ▶ Abnormal bone marrow function, defined as an absolute white cell count <3 × 10⁹/L or platelet count <100 × 10⁹/L.
- ▶ Pernicious anaemia or other megaloblastic anaemias where vitamin B₁₂ is deficient.
- ▶ Immunosuppressive therapy.
- ▶ Allergy or known intolerance to 5-fluorouracil (5-FU) or calcium folinate.
- ▶ Patients with a known lack of dihydropyrimidine-dehydrogenase (DPD) activity or patients treated with DPD inhibitors such as brivudine.
- ▶ Current pregnancy or breastfeeding; each pregnancy that occurs within 6 months after the termination of the perioperative chemotherapy has to be reported.
- ▶ History of another malignancy in the past 5 years.
- ▶ Inability to comply with the study and/or follow-up procedures.
- ▶ (Language) problems in understanding the patient information document explaining the present clinical trial.
- ▶ Concurrent participation in another clinical study.
- ▶ Any condition, which could result in an undue risk for the patient in the opinion of the investigator.

Study procedures**Perioperative chemotherapy**

Chemotherapy with 5-FU is started 12–18 hours prior to surgery and continued until postoperative day 1. Thereby

adequate systemic levels of cytotoxic substances will be reached during the critical period of tumour manipulation and potential intraoperative tumour cell dissemination. Overall, 1000 mg/m² 5-FU per day are applied for 48 hours (total dose 2000 mg/m²). The 5-FU infusion is administered via peripheral vein catheter. Immediately prior to 5-FU, 400 mg/m² calcium folinate will be given intravenously over 2 hours.

Surgery, biospecimen and data collection

(Partial) pancreaticoduodenectomy will be performed according to the standards of care in the Department of Surgery at Heidelberg University Hospital. Peripheral blood will be collected prior to the start of chemotherapy, as well as on postoperative days 3, 7, 14 (or day of discharge) and 30. Intraoperatively, peripheral and portal venous blood, bone marrow and tumour tissue dispensable for pathological diagnosis and staging will be collected for translational studies. The department's well-established and highly standardised local biobanks will be the backbone of this study. Perioperative management and postoperative care will be provided according to regular standards with particular attention to chemotherapy-associated side effects. In addition, on postoperative days 3, 7, 14 (or the day of discharge), qualified study personnel will visit the patient for the assessment of the study endpoints and to take peripheral blood. Thirty days after surgery, patients will be examined in the department's outpatient clinic for the occurrence of any further surgery-related or chemotherapy-related complications. Sixty days after surgery, patients will be contacted by telephone and asked for the occurrence of any further intervention-related complications. Adjuvant treatment regimens are performed according to current guidelines and in accordance with the recommendations of the National Centre of Tumour Disease of Heidelberg University Hospital, starting up to 12 weeks after surgery. Patients are followed until postoperative day 60.

Study endpoints**Primary study endpoint**

The primary objective of this study is to determine the safety of a perioperative chemotherapeutic regimen in combination with pancreatic cancer resection, which will be measured by the overall 30-day complication rate according to the Clavien-Dindo classification.⁵³ In parallel, the feasibility of this novel treatment concept will be assessed by the completeness of perioperative chemotherapy administration in relation to its toxicity, timely patient recruitment and proper collection of biospecimen.

Secondary study endpoints

Key secondary outcomes include:

- ▶ 60-day complication rate according to the Clavien-Dindo classification.⁵³
- ▶ 30-day and 60-day mortality.

- ▶ Pancreas-associated postoperative morbidity: POPF, PPH, DGE and chyle leak (according to the ISGPS definitions,³³⁻³⁷ intra-abdominal fluid collection or abscess.
- ▶ Bile leakage, including insufficiency of the biliodigestive anastomosis.
- ▶ Perioperative bleeding.
- ▶ Gastrointestinal bleeding.
- ▶ Postoperative ileus.
- ▶ Duration of intensive care unit stay (postoperative and readmissions).
- ▶ Postoperative duration of hospital stay.
- ▶ Need for readmission.
- ▶ Anaemia (Hb <80 g/L), thrombocytopaenia, leucopaenia.
- ▶ Postoperative sepsis.
- ▶ Allergic reactions.
- ▶ Serotonin syndrome.
- ▶ Mucositis (stomatitis, cheilitis, oesophagitis, proctitis), diarrhoea, nausea, vomiting.
- ▶ Alopecia, hand-and-foot syndrome.
- ▶ Central neurotoxicity, peripheral neuropathy.
- ▶ Renal failure (serum creatinine, blood urea nitrogen, urine production).
- ▶ Liver damage (AST>5×ULN, ALT>5×ULN, AP>5×ULN, GGT, bilirubin >1.5×ULN).
- ▶ Cardiotoxicity.
- ▶ Bronchospasm.
- ▶ Perioperative tumour cell dissemination (CTCs).
- ▶ Pharmacokinetics of perioperative chemotherapy.

Safety objectives and assessment of safety

The incidence of all adverse events (AEs) will be closely monitored and evaluated. Hereby, only events that occur after the study inclusion and during the follow-up period will be collected. All AEs and intervention-related side effects will be documented on the specific forms and will be reported regardless of causality. In addition, each serious AE (SAE) has to be documented on an SAE form and transmitted to the pharmacovigilance department within 24 hours after investigator's awareness of its occurrence. Following treatment of the first 10 patients recruitment will be interrupted for at least 30 days until an interim analysis for safety has been performed. If one of the following specific stopping criteria will be reached, the combiCaRe trial will be stopped immediately: grade B or C POPF^{33,34} in more than five patients; insufficiency of the biliodigestive anastomosis in more than four patients; death within 30 days in more than two patients.

Ancillary translational study

CTCs will be quantified, molecularly and functionally analysed in the systemic circulation and portal venous blood before, during and after pancreatic cancer resection. In addition, disseminated tumour cells (DTCs) in the bone marrow will be assessed via bone marrow biopsy during surgery. The effects of perioperative chemotherapy on CTC and DTC biology will be determined. The biodistribution

of 5-FU within pancreatic cancer tissue following perioperative 5-FU administration and oncological resection will be analysed and potential immediate effects of pharmacological interventions on tumour cell survival will be monitored in resected pancreatic cancer tissue. Comprehensive histopathological and molecular analyses will be performed for in-depth characterisation of immediate immune responses to chemotherapy-induced cell death in pancreatic cancer. Further functional assays using organ culture systems will help to determine the effect of 5-FU treatment on stroma-tumour cell cross-talk within an intact tumour microenvironment and provide a valuable in vitro tool for screening drugs with potential synergistic antitumour activity. This might help to design more efficient, personalised (immuno) therapies against pancreatic cancer.

Data handling and monitoring

All protocol-required information collected during the trial must be entered by the investigator, or designated representative, into the electronic case report form (eCRF). The completed eCRF must be reviewed and authorised electronically by the investigator or by a designated coinvestigator. To guarantee high data quality, data validation rules will be defined in a data validation plan. Completeness, validity and plausibility of data will be checked using a validating programme, which will generate queries. A tracking system for eCRF data and queries will be established to guarantee that data are managed in a timely manner. All data management procedures will be conducted according to written defined standard operating procedures of the Institute of Medical Biometry and Informatics at Heidelberg University Hospital that guarantee an efficient conduct complying with Good Clinical Practice (GCP). To ensure confidentiality of patients' personal information data will be stored and analysed in a pseudonymised manner and protected against unauthorised access. Only participating investigators or designated representatives will have the authority to access the data. Monitoring will be conducted by the Coordination Centre for Clinical Trials Heidelberg. The monitor ensures that the trial is conducted according to the study protocol and regulatory requirements by review of source documents, entries into the eCRF and essential documents.

Statistical analysis

The empirical distribution of all endpoints will be calculated, including mean, SD and quartiles in case of continuous variables and scores, and with absolute and relative frequencies in case of categorical data. Two-sided 95% CIs will be calculated. Descriptive p values of the corresponding statistical tests comparing the two samples (intraoperative chemotherapy and surgical resection vs surgical resection alone from contemporary control) will be reported. Whenever appropriate, statistical graphics will be used to visualise the findings. Besides an intention-to-treat (ITT) analysis, a modified ITT analysis will be performed to separately analyse patients receiving partial pancreaticoduodenectomy including a pancreaticodigestive anastomosis.

Ethics

The trial will be carried out in conformity with the 'ethical principles for medical research involving human subjects' of the 18th World Medical Association General Assembly in Helsinki (1964), including all amendments. The procedures set out in this study protocol, pertaining to the conduct, evaluation and documentation of this trial, are designed to ensure that all persons involved in the trial abide by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) harmonised tripartite guideline on GCP and the ethical principles described in the applicable version of the Declaration of Helsinki. The trial will be carried out in keeping with local legal and regulatory requirements. Thus, all measures have been taken to guarantee patient welfare and minimise ethical concerns. Any subsequent protocol amendments must be evaluated by the ethics committee and competent authority.

As described above, systemic chemotherapy during HIPEC is an established treatment regimen in colorectal cancer or other malignancies spread to the peritoneal cavity. 5-FU-based regimens have been shown to be effective in (neo)adjuvant and palliative pancreatic cancer therapy. Therefore, the perioperative application of 5-FU can be performed during a standard pancreatic cancer resection without expected SAEs. General complications of both, the chemotherapeutic regimen and surgical procedures, are subject of patients' informed and written consent. The occurrence of all treatment-emergent AEs, AEs, SAEs and suspected unexpected serious adverse reactions will be rigorously monitored. Immediate intervention or treatment is available in case of an acute AE.

Before being enrolled in the study, the subject is informed about the nature, scope and possible consequences of the study in a way understandable to the patient. An informed consent document that includes both information about the study (including ancillary translational study) and the consent form is prepared and given to the subject in a language understandable to the patient. After reading the informed consent document, the subject must give written informed consent to participate in the study. A copy of the signed consent document is given to the subject, and the original document is retained by the investigator. Without the patient's written informed consent, any measures or procedures required only for the clinical study are not permitted.

Patient and public involvement

Although patients or public were not involved in the design of the present study, our first priority was the patients' well-being. Patients will be informed about novel insights with regard to this clinical trial that might be relevant to their participation in this study. At any time, participants can be informed about study outcomes through the principal investigator. Furthermore, the results of this study are planned to be presented at meetings of self-supporting groups for patients with pancreatic

diseases and their relatives and friends, for example, the 'Arbeitskreis der Pankreatektomierten e.V.'.

Dissemination

The results of this trial will be presented at relevant national and international conferences and will be published in peer-reviewed journals, regardless of the outcome of this study. After analysis of the primary endpoint, a first manuscript reporting study results is planned to be published as soon as possible. All presentations and manuscripts will be reviewed by the principal investigator to prevent forfeiture of patient rights to data not in the public domain.

Author affiliations

¹Department of General, Visceral and Transplantation Surgery, Universitätsklinikum Heidelberg, Heidelberg, Germany

²Department of Medical Oncology, National Center for Tumor Diseases (NCT) and Heidelberg University Hospital, Heidelberg, Germany

³Department of Visceral, Vascular and Endocrine Surgery, Universitätsklinikum Halle, Halle, Germany

Acknowledgements We acknowledge financial support by Deutsche Forschungsgemeinschaft within the funding programme Open Access Publishing, by the Baden-Württemberg Ministry of Science, Research and the Arts and by Ruprecht-Karls-Universität Heidelberg.

Contributors SR, CS, MKD, CWM and TH designed the study protocol. CT, PK, UK and MM contributed to the study design. DJ, MWB and TH initiated this clinical study. SR and TH wrote the paper. All authors approved the final manuscript.

Funding The sponsor of this investigator initiated study is the Ruprecht-Karls-University Heidelberg, Medical Faculty, represented by the University Hospital Heidelberg (Im Neuenheimer Feld 672, 69 120 Heidelberg, Germany). This study is supported by the Heidelberger Stiftung Chirurgie.

Disclaimer The sponsor and funders have no role in the study design, data collection and analysis nor in publication of study results.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval The protocol of the combiCaRe trial (V.02, dated 27 July 2018) was approved by the German Federal Institute for Drugs and Medical Devices (reference number 4042787) on 20 August 2018 and reviewed by the Medical Ethics Committee of Heidelberg University that provided a favourable opinion (reference number AFmo-269/2018) on 11 September 2018.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin* 2018;68:7–30.
2. Kleeff J, Korc M, Apte M, *et al.* Pancreatic cancer. *Nat Rev Dis Primers* 2016;2.
3. O'Reilly D, Fou L, Hasler E, *et al.* Diagnosis and management of pancreatic cancer in adults: a summary of guidelines from the UK National Institute for health and care excellence. *Pancreatol* 2018;18:962–70.
4. Khorana AA, Mangu PB, Berlin J, *et al.* Potentially curable pancreatic cancer: American Society of clinical oncology clinical practice guideline update. *JCO* 2017;35:2324–8.
5. Seufferlein T, Porzner M, Becker T, *et al.* [S3-guideline exocrine pancreatic cancer]. *Z Gastroenterol* 2013;51:1395–440.

6. Tempero MA, Malafa MP, Al-Hawary M, *et al.* Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. *J Natl Compr Canc Netw* 2017;15:1028–61.
7. Bockhorn M, Uzunoglu FG, Adham M, *et al.* Borderline resectable pancreatic cancer: a consensus statement by the International Study group of pancreatic surgery (ISGPS). *Surgery* 2014;155:977–88.
8. Isaji S, Mizuno S, Windsor JA, *et al.* International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. *Pancreatol* 2018;18:2–11.
9. Beger HG, Rau B, Gansauge F, *et al.* Pancreatic cancer-low survival rates. *Dtsch Arztebl Int* 2008;105:255–62.
10. Hackert T, Büchler MW. Pancreatic cancer: advances in treatment, results and limitations. *Dig Dis* 2013;31:51–6.
11. Hartwig W, Werner J, Jäger D, *et al.* Improvement of surgical results for pancreatic cancer. *Lancet Oncol* 2013;14:e476–85.
12. Billimoria KY, Bentrem DJ, Ko CY, *et al.* National failure to operate on early stage pancreatic cancer. *Ann Surg* 2007;246:173–80.
13. Neoptolemos JP, Palmer DH, Ghaneh P, *et al.* Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. *Lancet* 2017;389:1011–24.
14. Uesaka K, Boku N, Fukutomi A, *et al.* Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). *The Lancet* 2016;388:248–57.
15. Kalsner MH, Ellenberg SS. Pancreatic cancer. adjuvant combined radiation and chemotherapy following curative resection. *Arch Surg* 1985;120:899–903.
16. Klinkenbijl JH, Jeekel J, Sahmoud T, *et al.* Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periaampullary region: phase III trial of the EORTC gastrointestinal tract cancer Cooperative group. *Ann Surg* 1999;230:776–82. discussion 82–4.
17. Neoptolemos JP, Dunn JA, Stocken DD, *et al.* Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. *Lancet* 2001;358:1576–85.
18. Neoptolemos JP, Stocken DD, Bassi C, *et al.* Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection. *JAMA* 2010;304:1073–81.
19. Neoptolemos JP, Stocken DD, Friess H, *et al.* A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. *N Engl J Med* 2004;350:1200–10.
20. Neoptolemos JP, Stocken DD, Tudur Smith C, *et al.* Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. *Br J Cancer* 2009;100:246–50.
21. Oettle H, Post S, Neuhaus P, *et al.* Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer. *JAMA* 2007;297:267–77.
22. Regine WF, Winter KA, Abrams R, *et al.* Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. *Ann Surg Oncol* 2011;18:1319–26.
23. Regine WF, Winter KA, Abrams RA, *et al.* Fluorouracil vs gemcitabine chemotherapy before and after Fluorouracil-Based chemoradiation following resection of pancreatic adenocarcinoma. *JAMA* 2008;299:1019–26.
24. Schmidt J, Abel U, Debus J, *et al.* Open-Label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. *JCO* 2012;30:4077–83.
25. Sinn M, Bahra M, Liersch T, *et al.* CONKO-005: adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial. *JCO* 2017;35:3330–7.
26. Hackert T, Sachsenmaier M, Hinz U, *et al.* Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With FOLFIRINOX Results in Resectability in 60% of the Patients. *Ann Surg* 2016;264:457–63.
27. Jang JY, Han Y, Lee H, *et al.* Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. *Ann Surg* 2018;268:215–22.
28. de Geus SWL, Eskander MF, Bliss LA, *et al.* Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: a nationwide propensity score matched analysis. *Surgery* 2017;161:592–601.
29. Mokdad AA, Minter RM, Zhu H, *et al.* Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. *JCO* 2017;35:515–22.
30. Ghaferi AA, Birkmeyer JD, Dimick JB. Variation in hospital mortality associated with inpatient surgery. *N Engl J Med* 2009;361:1368–75.
31. Joseph B, Morton JM, Hernandez-Boussard T, *et al.* Relationship between hospital volume, system clinical resources, and mortality in pancreatic resection. *J Am Coll Surg* 2009;208:520–7.
32. Krautz C, Nimptsch U, Weber GF, *et al.* Effect of hospital volume on in-hospital morbidity and mortality following pancreatic surgery in Germany. *Ann Surg* 2018;267:411–7.
33. Bassi C, Dervenis C, Butturini G, *et al.* Postoperative pancreatic fistula: an international Study Group (ISGPF) definition. *Surgery* 2005;138:8–13.
34. Bassi C, Marchegiani G, Dervenis C, *et al.* The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. *Surgery* 2016.
35. Wente MN, Bassi C, Dervenis C, *et al.* Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study group of pancreatic surgery (ISGPS). *Surgery* 2007;142:761–8.
36. Wente MN, Veit JA, Bassi C, *et al.* Postpancreatectomy hemorrhage (PPH)—An International Study Group of Pancreatic Surgery (ISGPS) definition. *Surgery* 2007;142:20–5.
37. Besselink MG, van Rijssen LB, Bassi C, *et al.* Definition and classification of chyle leak after pancreatic operation: a consensus statement by the International Study Group on pancreatic surgery. *Surgery* 2017;161:365–72.
38. Griffin JF, Smalley SR, Jewell W, *et al.* Patterns of failure after curative resection of pancreatic carcinoma. *Cancer* 1990;66:56–61.
39. Sperti C, Pasquali C, Piccoli A, *et al.* Recurrence after resection for ductal adenocarcinoma of the pancreas. *World J Surg* 1997;21:195–200.
40. Takamori H, Hiraoka T, Kanemitsu K, *et al.* Pancreatic liver metastases after curative resection combined with intraoperative radiation for pancreatic cancer. *Hepatogastroenterology* 2004;51:1500–3.
41. Haeno H, Gonen M, Davis MB, *et al.* Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. *Cell* 2012;148:362–75.
42. Rhim AD, Mirek ET, Aiello NM, *et al.* Emt and dissemination precede pancreatic tumor formation. *Cell* 2012;148:349–61.
43. Sugarbaker PH. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. *Cancer Treat Res* 1996;82:79–100.
44. Gall TMH, Jacob J, Frampton AE, *et al.* Reduced dissemination of circulating tumor cells with no-touch isolation surgical technique in patients with pancreatic cancer. *JAMA Surg* 2014;149:482–5.
45. Court CM, Ankeny JS, Sho S, *et al.* Circulating tumor cells predict occult metastatic disease and prognosis in pancreatic cancer. *Ann Surg Oncol* 2018;25:1000–8.
46. Gemenetzis G, Groot VP, Yu J, *et al.* Circulating tumor cells dynamics in pancreatic adenocarcinoma correlate with disease status: results of the prospective cluster study. *Ann Surg* 2018;268:408–20.
47. Huguenschmidt H, Labori KJ, Brunborg C, *et al.* Circulating tumor cells are an independent predictor of shorter survival in patients undergoing resection for pancreatic and periaampullary adenocarcinoma. *Ann Surg* 2018;1.
48. Tentes A-AK, Kyziridis D, Kakolyris S, *et al.* Preliminary results of hyperthermic intraperitoneal intraoperative chemotherapy as an adjuvant in resectable pancreatic cancer. *Gastroenterol Res Pract* 2012;2012:1–5.
49. Kulu Y, Müller-Stich B, Büchler MW, *et al.* Surgical treatment of peritoneal carcinomatosis: current treatment modalities. *Langenbecks Arch Surg* 2014;399:41–53.
50. Vanounou T, Garfinkle R. Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin in the era of value-based medicine. *Ann Surg Oncol* 2016;23:2556–61.
51. Takamori H, Kanemitsu K, Hirota M, *et al.* Perioperative intra-arterial and systemic chemotherapy for pancreatic cancer. *Ann Surg Oncol* 2011;18:1110–5.
52. Chan A-W, Tetzlaff JM, Altman DG, *et al.* SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Ann Intern Med* 2013;158:200–7.
53. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004;240:205–13.

Correction: Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer: the combiCaRe study

Roth S, Springfield C, Diener MK, et al Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer: the combiCaRe study. *BMJ Open* 2019;9:e028696. doi: 10.1136/bmjopen-2018-028696

This article was previously published with error in author name.
The correct name for last author is Thilo Hackert.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

BMJ Open 2019;9:e028696corr1. doi:10.1136/bmjopen-2018-028696corr1